메뉴 건너뛰기




Volumn 8, Issue 2, 2008, Pages 235-257

Pharmacotherapy for social anxiety disorder: A systematic review

Author keywords

Monoamine oxidase inhibitor; Pharmacotherapy; Randomized controlled trial; Reversible inhibitor of monoamine oxidase A; Selective serotonin reuptake inhibitor; Serotonin noradrenaline reuptake inhibitor; Social anxiety disorder; Social phobia

Indexed keywords

ATENOLOL; BROFAROMINE; BROMAZEPAM; BUSPIRONE; CITALOPRAM; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; SEROTONIN; SERTRALINE; TACHYKININ RECEPTOR ANTAGONIST; VENLAFAXINE;

EID: 39549108710     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.2.235     Document Type: Review
Times cited : (54)

References (139)
  • 1
    • 0013942402 scopus 로고
    • Different ages of onset in varieties of phobias
    • Marks IM, Gelder MG. Different ages of onset in varieties of phobias. Am. J. Psychiatry 123(2), 218-221 (1966).
    • (1966) Am. J. Psychiatry , vol.123 , Issue.2 , pp. 218-221
    • Marks, I.M.1    Gelder, M.G.2
  • 2
    • 0004235298 scopus 로고
    • American Psychiatric Association, American Psychiatric Press, Washington, DC, USA
    • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington, DC, USA (1980).
    • (1980) Diagnostic and Statistical Manual of Mental Disorders
  • 3
    • 20344374645 scopus 로고    scopus 로고
    • Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication
    • Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 617-627 (2005).
    • (2005) Arch. Gen. Psychiatry , vol.62 , Issue.6 , pp. 617-627
    • Kessler, R.C.1    Chiu, W.T.2    Demler, O.3    Merikangas, K.R.4    Walters, E.E.5
  • 4
    • 0035178428 scopus 로고    scopus 로고
    • Impact of generalized social anxiety disorder in managed care
    • Katzelnick DJ, Kobak KA, DeLeire T et al. Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry 158(12), 1999-2007 (2001).
    • (2001) Am. J. Psychiatry , vol.158 , Issue.12 , pp. 1999-2007
    • Katzelnick, D.J.1    Kobak, K.A.2    DeLeire, T.3
  • 5
    • 0029852396 scopus 로고    scopus 로고
    • The impact of social phobia on quality of life. International Clinical
    • Wittchen H, Beloch E. The impact of social phobia on quality of life. International Clinical Int. Clin. Psychopharmacol. 11(Suppl. 3), 15-23 (1996).
    • (1996) Int. Clin. Psychopharmacol , vol.11 , Issue.SUPPL. 3 , pp. 15-23
    • Wittchen, H.1    Beloch, E.2
  • 6
    • 20344385026 scopus 로고    scopus 로고
    • Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication
    • Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62(6), 593-602 (2005).
    • (2005) Arch. Gen. Psychiatry , vol.62 , Issue.6 , pp. 593-602
    • Kessler, R.C.1    Berglund, P.2    Demler, O.3
  • 7
    • 39549099619 scopus 로고    scopus 로고
    • Paroxetine in social anxiety disorder: A remission analysis
    • Presented at:, Barcelona, Spain, 5-9 October
    • Stein DJ, Hunter B, Rolfe T. Paroxetine in social anxiety disorder: a remission analysis. Presented at: 15th ECNP Congress. Barcelona, Spain, 5-9 October 2002.
    • (2002) 15th ECNP Congress
    • Stein, D.J.1    Hunter, B.2    Rolfe, T.3
  • 8
    • 0031984593 scopus 로고    scopus 로고
    • A direct-interview family study of generalized social phobia
    • Stein MB, Chartier MJ, Hazen AL et al. A direct-interview family study of generalized social phobia. Am. J. Psychiatry 155(1), 90-97 (1998).
    • (1998) Am. J. Psychiatry , vol.155 , Issue.1 , pp. 90-97
    • Stein, M.B.1    Chartier, M.J.2    Hazen, A.L.3
  • 9
    • 0033855524 scopus 로고    scopus 로고
    • Social phobia in a population-based female adolescent twin sample: Co-morbidity and associated suicide-related symptoms
    • Nelson EC, Grant JD, Bucholz KK et al. Social phobia in a population-based female adolescent twin sample: co-morbidity and associated suicide-related symptoms. Psychol. Med. 30(4), 797-804 (2000).
    • (2000) Psychol. Med , vol.30 , Issue.4 , pp. 797-804
    • Nelson, E.C.1    Grant, J.D.2    Bucholz, K.K.3
  • 11
    • 0035010604 scopus 로고    scopus 로고
    • Psychological and pharmacological treatments of social phobia
    • Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia. J. Clin. Psychopharmacol. 21(3), 311-324 (2001).
    • (2001) J. Clin. Psychopharmacol , vol.21 , Issue.3 , pp. 311-324
    • Fedoroff, I.C.1    Taylor, S.2
  • 12
    • 0031735121 scopus 로고    scopus 로고
    • Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 59(Suppl. 17), 54-60 (1998). • Although dated, this is still the only published clinical guideline devoted exclusively to the treatment of social anxiety disorder (SAD) with pharmacotherapy. Describes the epidemiology of SAD, associated comorbidity and the burdens imposed by this disorder. Each section contains recommendations for future research, many of which are still pertinent today.
    • Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 59(Suppl. 17), 54-60 (1998). • Although dated, this is still the only published clinical guideline devoted exclusively to the treatment of social anxiety disorder (SAD) with pharmacotherapy. Describes the epidemiology of SAD, associated comorbidity and the burdens imposed by this disorder. Each section contains recommendations for future research, many of which are still pertinent today.
  • 13
    • 0038810202 scopus 로고    scopus 로고
    • WFSBP task force on treatment guidelines for anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders
    • Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. WFSBP task force on treatment guidelines for anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J. Biol. Psychiatry 3(4), 171-199 (2002).
    • (2002) World J. Biol. Psychiatry , vol.3 , Issue.4 , pp. 171-199
    • Bandelow, B.1    Zohar, J.2    Hollander, E.3    Kasper, S.4    Moller, H.J.5
  • 14
    • 0036249434 scopus 로고    scopus 로고
    • Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy
    • Furmark T, Tillfors M, Marteinsdottir I et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch. Gen. Psychiatry 59(5), 425-433 (2002).
    • (2002) Arch. Gen. Psychiatry , vol.59 , Issue.5 , pp. 425-433
    • Furmark, T.1    Tillfors, M.2    Marteinsdottir, I.3
  • 15
    • 0015856823 scopus 로고
    • A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety
    • Tyrer P, Candy J, Kelly D. A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia 32(3), 237-254 (1973).
    • (1973) Psychopharmacologia , vol.32 , Issue.3 , pp. 237-254
    • Tyrer, P.1    Candy, J.2    Kelly, D.3
  • 16
    • 0023281158 scopus 로고
    • Drug treatment of social phobia
    • Gorman JM, Gorman LK. Drug treatment of social phobia. J. Affect. Disord. 13(2), 183-192 (1987).
    • (1987) J. Affect. Disord , vol.13 , Issue.2 , pp. 183-192
    • Gorman, J.M.1    Gorman, L.K.2
  • 17
    • 0026640346 scopus 로고
    • Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
    • Versiani M, Nardi AE, Mundim FD et al. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br. J. Psychiatry 161, 353-360 (1992).
    • (1992) Br. J. Psychiatry , vol.161 , pp. 353-360
    • Versiani, M.1    Nardi, A.E.2    Mundim, F.D.3
  • 19
    • 0033736350 scopus 로고    scopus 로고
    • The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials
    • van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int. Clin. Psychopharmacol. 15 (Suppl. 2), 15-24 (2000).
    • (2000) Int. Clin. Psychopharmacol , vol.15 , Issue.SUPPL. 2 , pp. 15-24
    • van der Linden, G.J.1    Stein, D.J.2    van Balkom, A.J.3
  • 20
    • 0026826649 scopus 로고
    • Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
    • van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur. Neuropsychopharmacol. 2(1), 21-29 (1992).
    • (1992) Eur. Neuropsychopharmacol , vol.2 , Issue.1 , pp. 21-29
    • van Vliet, I.M.1    den Boer, J.A.2    Westenberg, H.G.3
  • 22
    • 0036182223 scopus 로고    scopus 로고
    • Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials
    • Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J. Clin. Psychiatry 63(2), 152-155 (2002).
    • (2002) J. Clin. Psychiatry , vol.63 , Issue.2 , pp. 152-155
    • Stein, D.J.1    Stein, M.B.2    Pitts, C.D.3    Kumar, R.4    Hunter, B.5
  • 24
    • 0031792868 scopus 로고    scopus 로고
    • Pharmacotherapy of social anxiety disorder
    • Davidson JR. Pharmacotherapy of social anxiety disorder. J. Clin. Psychiatry 59(Suppl. 17), 47-51 (1998).
    • (1998) J. Clin. Psychiatry , vol.59 , Issue.SUPPL. 17 , pp. 47-51
    • Davidson, J.R.1
  • 25
    • 0036153567 scopus 로고    scopus 로고
    • Pharmacotherapy of social anxiety disorder
    • Blanco C, Antia SX, Liebowitz MR. Pharmacotherapy of social anxiety disorder. Biol. Psychiatry 51(1), 109-120 (2002).
    • (2002) Biol. Psychiatry , vol.51 , Issue.1 , pp. 109-120
    • Blanco, C.1    Antia, S.X.2    Liebowitz, M.R.3
  • 26
    • 33845807475 scopus 로고    scopus 로고
    • The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A metaanalysis of double-blind, placebo-controlled trials
    • Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a metaanalysis of double-blind, placebo-controlled trials. J. Psychopharmacol. (Oxford) 21(1), 102-111 (2007).
    • (2007) J. Psychopharmacol. (Oxford) , vol.21 , Issue.1 , pp. 102-111
    • Hedges, D.W.1    Brown, B.L.2    Shwalb, D.A.3    Godfrey, K.4    Larcher, A.M.5
  • 27
    • 0042472877 scopus 로고    scopus 로고
    • Pharmalogical treatment of social anxiety disorder: A meta-analysis
    • Blanco C, Schneier FR, Schmidt A et al. Pharmalogical treatment of social anxiety disorder: a meta-analysis. Depress. Anxiety 18, 29-40 (2003).
    • (2003) Depress. Anxiety , vol.18 , pp. 29-40
    • Blanco, C.1    Schneier, F.R.2    Schmidt, A.3
  • 28
    • 85100415918 scopus 로고    scopus 로고
    • Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. John Wiley & Sons Ltd, Chichester, UK (2006).
    • Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Updated September 2006. John Wiley & Sons Ltd, Chichester, UK (2006).
  • 29
    • 0036203445 scopus 로고    scopus 로고
    • Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed
    • Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int. J. Epidemiol. 31(1), 150-153 (2002).
    • (2002) Int. J. Epidemiol , vol.31 , Issue.1 , pp. 150-153
    • Robinson, K.A.1    Dickersin, K.2
  • 30
    • 39549107015 scopus 로고    scopus 로고
    • World Health Organisation. The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organisation (Ed.), Geneva, Switzerland (1975).
    • World Health Organisation. The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organisation (Ed.), Geneva, Switzerland (1975).
  • 33
    • 0032956810 scopus 로고    scopus 로고
    • Psychometric properties of the Liebowitz Social Anxiety Scale
    • Heimberg RG, Horner KJ, Juster HR et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol. Med. 29(1), 199-212 (1999).
    • (1999) Psychol. Med , vol.29 , Issue.1 , pp. 199-212
    • Heimberg, R.G.1    Horner, K.J.2    Juster, H.R.3
  • 35
    • 0018425438 scopus 로고
    • A new depression scale designed to be sensitive to change
    • Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389 (1979).
    • (1979) Br. J. Psychiatry , vol.134 , pp. 382-389
    • Montgomery, S.A.1    Asberg, M.2
  • 37
    • 0034750007 scopus 로고    scopus 로고
    • Development of a quality assessment instrument for trials of treatments for depression and neurosis
    • Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. Int. J. Methods Psychiatr. Res. 10(3), 126-133 (2001).
    • (2001) Int. J. Methods Psychiatr. Res , vol.10 , Issue.3 , pp. 126-133
    • Moncrieff, J.1    Churchill, R.2    Drummond, D.C.3    McGuire, H.4
  • 39
    • 0030800198 scopus 로고    scopus 로고
    • Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
    • Lott M, Greist JH, Jefferson JW et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J. Clin. Psychopharmacol. 17(4), 255-260 (1997).
    • (1997) J. Clin. Psychopharmacol , vol.17 , Issue.4 , pp. 255-260
    • Lott, M.1    Greist, J.H.2    Jefferson, J.W.3
  • 42
    • 39549120547 scopus 로고    scopus 로고
    • Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.5. Updated May 2005. The Cochrane Library (2005).
    • Deeks J, Higgins J, Altman D. Cochrane Reviewers' Handbook 4.2.5. Updated May 2005. The Cochrane Library (2005).
  • 44
    • 84948773232 scopus 로고    scopus 로고
    • Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis
    • Edition. BMJ, London, UK 2001
    • nd Edition. BMJ, London, UK (2001).
    • nd
    • Deeks, J.J.1    Altman, D.G.2    Bradburn, M.J.3
  • 45
    • 0043198131 scopus 로고    scopus 로고
    • Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events?
    • Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials - a reflection of treatment effect or adverse events? J. Am. Med. Assoc. 290, 921-928 (2003).
    • (2003) J. Am. Med. Assoc , vol.290 , pp. 921-928
    • Als-Nielsen, B.1    Chen, W.2    Gluud, C.3    Kjaergard, L.L.4
  • 47
    • 0032789136 scopus 로고    scopus 로고
    • Treatment of social phobia with gabapentin: A placebo-controlled study
    • Pande AC, Davidson JR, Jefferson JW et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. 19(4), 341-348 (1999).
    • (1999) J. Clin. Psychopharmacol , vol.19 , Issue.4 , pp. 341-348
    • Pande, A.C.1    Davidson, J.R.2    Jefferson, J.W.3
  • 48
    • 0034946458 scopus 로고    scopus 로고
    • Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia
    • Blomhoff S, Haug TT, Hellstrom K et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br. J. Psychiatry 179, 23-30 (2001).
    • (2001) Br. J. Psychiatry , vol.179 , pp. 23-30
    • Blomhoff, S.1    Haug, T.T.2    Hellstrom, K.3
  • 49
    • 0029094582 scopus 로고
    • Sertraline for social phobia: A double-blind, placebo-controlled crossover study
    • Katzelnick DJ, Kobak KA, Greist JH et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am. J. Psychiatry 152(9), 1368-1371 (1995).
    • (1995) Am. J. Psychiatry , vol.152 , Issue.9 , pp. 1368-1371
    • Katzelnick, D.J.1    Kobak, K.A.2    Greist, J.H.3
  • 50
    • 33847609653 scopus 로고    scopus 로고
    • Nefazodone in the treatment of generalized social phobia: A randomized, placebo-controlled trial
    • Van Ameringen M, Mancini C, Oakman J et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J. Clin. Psychiatry 68(2), 288-295 (2007).
    • (2007) J. Clin. Psychiatry , vol.68 , Issue.2 , pp. 288-295
    • Van Ameringen, M.1    Mancini, C.2    Oakman, J.3
  • 51
    • 27944497365 scopus 로고    scopus 로고
    • Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study
    • Muehlbacher M, Nickel MK, Nickel C et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 25(6), 580-583 (2005).
    • (2005) J. Clin. Psychopharmacol , vol.25 , Issue.6 , pp. 580-583
    • Muehlbacher, M.1    Nickel, M.K.2    Nickel, C.3
  • 52
    • 22444442937 scopus 로고    scopus 로고
    • Furmark T, Appel L, Michelgard A et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58(2), 132-142 (2005). •• A novel brain imaging study in which the participants with SAD engaged in public speaking prior to and following 6 weeks of treatment with the Neurokinin-1 receptor antagonist GR205171, citalopram and placebo. Hypothesized reductions in blood flow in the medial temporal lobe (including the hippocampus and amygdala) were observed in both treatment groups, and were associated with large reductions in anxiety and treatment response on the Clinical Global Impressions Improvement scale.
    • Furmark T, Appel L, Michelgard A et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 58(2), 132-142 (2005). •• A novel brain imaging study in which the participants with SAD engaged in public speaking prior to and following 6 weeks of treatment with the Neurokinin-1 receptor antagonist GR205171, citalopram and placebo. Hypothesized reductions in blood flow in the medial temporal lobe (including the hippocampus and amygdala) were observed in both treatment groups, and were associated with large reductions in anxiety and treatment response on the Clinical Global Impressions Improvement scale.
  • 53
    • 0025757170 scopus 로고
    • The assessment and treatment of performance anxiety in musicians
    • Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am. J. Psychiatry 148(5), 598-605 (1991).
    • (1991) Am. J. Psychiatry , vol.148 , Issue.5 , pp. 598-605
    • Clark, D.B.1    Agras, W.S.2
  • 54
    • 0028334924 scopus 로고
    • Social phobia: A comparison of behaviour therapy and atenolol
    • Turner S, Beidel DC, Jacob RG. Social phobia: a comparison of behaviour therapy and atenolol. J. Consult. Clin. Psychol. 62(2), 350-358 (1994).
    • (1994) J. Consult. Clin. Psychol , vol.62 , Issue.2 , pp. 350-358
    • Turner, S.1    Beidel, D.C.2    Jacob, R.G.3
  • 55
    • 0026516493 scopus 로고
    • Phenelzine vs atenolol in social phobia: A placebo-controlled comparison
    • Liebowitz MR, Schneier F, Campeas R et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch. Gen. Psychiatry 49(4), 290-300 (1992).
    • (1992) Arch. Gen. Psychiatry , vol.49 , Issue.4 , pp. 290-300
    • Liebowitz, M.R.1    Schneier, F.2    Campeas, R.3
  • 56
    • 4444333450 scopus 로고    scopus 로고
    • Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine
    • Allgulander C, Mangano R, Zhang J et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 19(6), 387-396 (2004).
    • (2004) Hum. Psychopharmacol , vol.19 , Issue.6 , pp. 387-396
    • Allgulander, C.1    Mangano, R.2    Zhang, J.3
  • 57
    • 14644404240 scopus 로고    scopus 로고
    • Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, Group SADS. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66(2), 238-247 (2005).
    • Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, Group SADS. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 66(2), 238-247 (2005).
  • 58
    • 3543043767 scopus 로고    scopus 로고
    • Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study
    • Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety 19(4), 241-248 (2004).
    • (2004) Depress. Anxiety , vol.19 , Issue.4 , pp. 241-248
    • Lader, M.1    Stender, K.2    Burger, V.3    Nil, R.4
  • 59
    • 12344249711 scopus 로고    scopus 로고
    • Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial
    • Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl.) 177(3), 280-288 (2005).
    • (2005) Psychopharmacology (Berl.) , vol.177 , Issue.3 , pp. 280-288
    • Stein, M.B.1    Pollack, M.H.2    Bystritsky, A.3    Kelsey, J.E.4    Mangano, R.M.5
  • 60
    • 0031736386 scopus 로고    scopus 로고
    • Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome
    • Heimberg RG, Liebowitz MR, Hope DA et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch. Gen. Psychiatry 55(12), 1133-1141 (1998).
    • (1998) Arch. Gen. Psychiatry , vol.55 , Issue.12 , pp. 1133-1141
    • Heimberg, R.G.1    Liebowitz, M.R.2    Hope, D.A.3
  • 61
    • 0028785771 scopus 로고
    • Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study
    • Fahlen T, Nilsson H, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr. Scand. 92(5), 351-358 (1995).
    • (1995) Acta Psychiatr. Scand , vol.92 , Issue.5 , pp. 351-358
    • Fahlen, T.1    Nilsson, H.2    Borg, K.3    Humble, M.4    Pauli, U.5
  • 62
    • 8244233845 scopus 로고    scopus 로고
    • Moclobemide in social phobia. A double-blind, placebo-controlled clinical study
    • Katschnig K, Stein MB, Buller R. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur. Arch. Psychiatry Clin. Neurosci. 247(2), 71-80 (1997).
    • (1997) Eur. Arch. Psychiatry Clin. Neurosci , vol.247 , Issue.2 , pp. 71-80
    • Katschnig, K.1    Stein, M.B.2    Buller, R.3
  • 63
    • 0343683384 scopus 로고    scopus 로고
    • Moclobemide in social phobia: A controlled dose response trial
    • Noyes R Jr, Moroz G, Davidson JR et al. Moclobemide in social phobia: a controlled dose response trial. J. Clin. Psychopharmacol. 17(4), 247-254 (1997).
    • (1997) J. Clin. Psychopharmacol , vol.17 , Issue.4 , pp. 247-254
    • Noyes Jr, R.1    Moroz, G.2    Davidson, J.R.3
  • 65
    • 0031912874 scopus 로고    scopus 로고
    • Placebo-controlled trial of moclobemide in social phobia
    • Schneier FR, Goetz D, Campeas R et al. Placebo-controlled trial of moclobemide in social phobia. Br. J. Psychiatry 172, 70-77 (1998).
    • (1998) Br. J. Psychiatry , vol.172 , pp. 70-77
    • Schneier, F.R.1    Goetz, D.2    Campeas, R.3
  • 66
    • 0035985962 scopus 로고    scopus 로고
    • Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
    • Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int. Clin. Psychopharmacol. 17(4), 161-170 (2002).
    • (2002) Int. Clin. Psychopharmacol , vol.17 , Issue.4 , pp. 161-170
    • Stein, D.J.1    Cameron, A.2    Amrein, R.3    Montgomery, S.A.4
  • 67
    • 14844291585 scopus 로고    scopus 로고
    • Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
    • Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry 186, 222-226 (2005).
    • (2005) Br. J. Psychiatry , vol.186 , pp. 222-226
    • Kasper, S.1    Stein, D.J.2    Loft, H.3    Nil, R.4
  • 68
    • 5044229135 scopus 로고    scopus 로고
    • Fluoxetine, comprehensive cogntive behavioral therapy, and placebo in generalised social phobia
    • Davidson JRT, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cogntive behavioral therapy, and placebo in generalised social phobia. Arch. Gen. Psychiatry 61, 1005-1013 (2004).
    • (2004) Arch. Gen. Psychiatry , vol.61 , pp. 1005-1013
    • Davidson, J.R.T.1    Foa, E.B.2    Huppert, J.D.3
  • 70
    • 33847038810 scopus 로고    scopus 로고
    • Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study
    • Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 10(2), 263-267 (2007).
    • (2007) Int. J. Neuropsychopharmacol , vol.10 , Issue.2 , pp. 263-267
    • Asakura, S.1    Tajima, O.2    Koyama, T.3
  • 71
    • 1642307074 scopus 로고    scopus 로고
    • Fluvoxamine- controlled release formulation for the treatment of generalized social anxiety disorder
    • Davidson J, Yaryura-Tobias J, DuPont R et al. Fluvoxamine- controlled release formulation for the treatment of generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(2), 118-125 (2004).
    • (2004) J. Clin. Psychopharmacol , vol.24 , Issue.2 , pp. 118-125
    • Davidson, J.1    Yaryura-Tobias, J.2    DuPont, R.3
  • 72
    • 0032894805 scopus 로고    scopus 로고
    • Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebocontrolled study
    • Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebocontrolled study. Am. J. Psychiatry 156(5), 756-760 (1999).
    • (1999) Am. J. Psychiatry , vol.156 , Issue.5 , pp. 756-760
    • Stein, M.B.1    Fyer, A.J.2    Davidson, J.R.3    Pollack, M.H.4    Wiita, B.5
  • 73
    • 0028340187 scopus 로고
    • Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine
    • van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl.) 115(1-2), 128-134 (1994).
    • (1994) Psychopharmacology (Berl.) , vol.115 , Issue.1-2 , pp. 128-134
    • van Vliet, I.M.1    den Boer, J.A.2    Westenberg, H.G.3
  • 74
    • 1642539050 scopus 로고    scopus 로고
    • A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder
    • Westenberg HGM, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(1), 49-55 (2005).
    • (2005) J. Clin. Psychopharmacol , vol.24 , Issue.1 , pp. 49-55
    • Westenberg, H.G.M.1    Stein, D.J.2    Yang, H.3    Li, D.4    Barbato, L.M.5
  • 75
    • 0032867886 scopus 로고    scopus 로고
    • Paroxetine in social social anxiety disorder: A randomised placebo-controlled study
    • Allgulander C. Paroxetine in social social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatr. Scand. 100(3), 193-198 (1999).
    • (1999) Acta Psychiatr. Scand , vol.100 , Issue.3 , pp. 193-198
    • Allgulander, C.1
  • 76
    • 0032773913 scopus 로고    scopus 로고
    • Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study
    • Baldwin D, Bobes J, Stein DJ, Scharwaechter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 175, 120-126 (1999).
    • (1999) Br. J. Psychiatry , vol.175 , pp. 120-126
    • Baldwin, D.1    Bobes, J.2    Stein, D.J.3    Scharwaechter, I.4    Faure, M.5
  • 77
    • 0036152363 scopus 로고    scopus 로고
    • A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder
    • Liebowitz MR, Stein MB, Tancer M et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J. Clin. Psychiatry 63(1), 66-74 (2002).
    • (2002) J. Clin. Psychiatry , vol.63 , Issue.1 , pp. 66-74
    • Liebowitz, M.R.1    Stein, M.B.2    Tancer, M.3
  • 78
    • 1842866930 scopus 로고    scopus 로고
    • Controlled-release paroxetine in the treatment of patients with social anxiety disorder
    • Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J. Clin. Psychiatry 65(2), 222-229 (2004).
    • (2004) J. Clin. Psychiatry , vol.65 , Issue.2 , pp. 222-229
    • Lepola, U.1    Bergtholdt, B.2    St Lambert, J.3    Davy, K.L.4    Ruggiero, L.5
  • 79
    • 0035665364 scopus 로고    scopus 로고
    • Paroxetine for social anxiety and alcohol use in dual-diagnosed patients
    • Randall CL, Johnson MR, Thevos AK et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress. Anxiety 14(4), 255-262 (2001).
    • (2001) Depress. Anxiety , vol.14 , Issue.4 , pp. 255-262
    • Randall, C.L.1    Johnson, M.R.2    Thevos, A.K.3
  • 80
    • 0030014796 scopus 로고    scopus 로고
    • Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
    • Stein MB, Chartier MJ, Hazen AL et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J. Clin. Psychopharmacol. 16(3), 218-222 (1996).
    • (1996) J. Clin. Psychopharmacol , vol.16 , Issue.3 , pp. 218-222
    • Stein, M.B.1    Chartier, M.J.2    Hazen, A.L.3
  • 81
    • 0001229940 scopus 로고    scopus 로고
    • Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder
    • S
    • Kumar R, Pitts C, Carpenter D. Response to paroxetine is maintained during continued treatment in patients with social anxiety disorder. Eur. Neuropsychopharmacol. 9(Suppl. 5), S312 (1999).
    • (1999) Eur. Neuropsychopharmacol , vol.9 , Issue.SUPPL. 5 , pp. 312
    • Kumar, R.1    Pitts, C.2    Carpenter, D.3
  • 82
    • 0032569245 scopus 로고    scopus 로고
    • Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
    • Stein MB, Liebowitz MR, Lydiard RB et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J. Am. Med. Assoc. 280(8), 708-713 (1998).
    • (1998) J. Am. Med. Assoc , vol.280 , Issue.8 , pp. 708-713
    • Stein, M.B.1    Liebowitz, M.R.2    Lydiard, R.B.3
  • 83
    • 0042306153 scopus 로고    scopus 로고
    • Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study
    • Liebowitz MR, DeMartinis N, Weihs KL et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J. Clin. Psychiatry 64(7), 785-792 (2003).
    • (2003) J. Clin. Psychiatry , vol.64 , Issue.7 , pp. 785-792
    • Liebowitz, M.R.1    DeMartinis, N.2    Weihs, K.L.3
  • 84
    • 0035146313 scopus 로고    scopus 로고
    • Sertraline treatment of generalised social phobia: A 20-week, double-blind, placebo-controlled study
    • Van Ameringen MA, Lane RM, Walker JR et al. Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry 158(2), 275-281 (2001).
    • (2001) Am. J. Psychiatry , vol.158 , Issue.2 , pp. 275-281
    • Van Ameringen, M.A.1    Lane, R.M.2    Walker, J.R.3
  • 85
    • 13244255707 scopus 로고    scopus 로고
    • Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder
    • Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 62(2), 190-198 (2005).
    • (2005) Arch. Gen. Psychiatry , vol.62 , Issue.2 , pp. 190-198
    • Liebowitz, M.R.1    Gelenberg, A.J.2    Munjack, D.3
  • 86
    • 4644343737 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder
    • Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 24(5), 488-496 (2004).
    • (2004) J. Clin. Psychopharmacol , vol.24 , Issue.5 , pp. 488-496
    • Rickels, K.1    Mangano, R.2    Khan, A.3
  • 87
    • 0030982241 scopus 로고    scopus 로고
    • Clinical effects of busiprone in social phobia: A double-blind placebo-controlled study
    • van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of busiprone in social phobia: a double-blind placebo-controlled study. J. Clin. Psychiatry 58(4), 164-168 (1997).
    • (1997) J. Clin. Psychiatry , vol.58 , Issue.4 , pp. 164-168
    • van Vliet, I.M.1    den Boer, J.A.2    Westenberg, H.G.3    Pian, K.L.4
  • 88
    • 0031706618 scopus 로고    scopus 로고
    • Discontinuation of clonazepam in the treatment of social phobia
    • Connor KM, Davidson JR, Potts NL et al. Discontinuation of clonazepam in the treatment of social phobia. J. Clin. Psychopharmacol. 18(5), 373-378 (1998).
    • (1998) J. Clin. Psychopharmacol , vol.18 , Issue.5 , pp. 373-378
    • Connor, K.M.1    Davidson, J.R.2    Potts, N.L.3
  • 89
    • 0027764363 scopus 로고
    • Treatment of social phobia with clonazepan and placebo
    • Davidson JR, Potts N, Richichi E et al. Treatment of social phobia with clonazepan and placebo. J. Clin. Psychopharmacol. 13(6), 423-428 (1993).
    • (1993) J. Clin. Psychopharmacol , vol.13 , Issue.6 , pp. 423-428
    • Davidson, J.R.1    Potts, N.2    Richichi, E.3
  • 90
    • 25844473118 scopus 로고    scopus 로고
    • Levetiracetam in social phobia: A placebo controlled pilot study
    • Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J. Psychopharmacol. (Oxford) 19(5), 551-553 (2005).
    • (2005) J. Psychopharmacol. (Oxford) , vol.19 , Issue.5 , pp. 551-553
    • Zhang, W.1    Connor, K.M.2    Davidson, J.R.3
  • 91
    • 12144285831 scopus 로고    scopus 로고
    • Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study
    • Pande A, Feltner D, Jefferson J et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 24(2), 141-149 (2004).
    • (2004) J. Clin. Psychopharmacol , vol.24 , Issue.2 , pp. 141-149
    • Pande, A.1    Feltner, D.2    Jefferson, J.3
  • 92
    • 27544443726 scopus 로고    scopus 로고
    • A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder
    • Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J. Clin. Psychiatry 66(10), 1270-1278 (2005).
    • (2005) J. Clin. Psychiatry , vol.66 , Issue.10 , pp. 1270-1278
    • Montgomery, S.A.1    Nil, R.2    Durr-Pal, N.3    Loft, H.4    Boulenger, J.P.5
  • 93
    • 0036895568 scopus 로고    scopus 로고
    • Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study
    • Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch. Gen. Psychiatry 59(12), 1111-1118 (2002).
    • (2002) Arch. Gen. Psychiatry , vol.59 , Issue.12 , pp. 1111-1118
    • Stein, D.J.1    Versiani, M.2    Hair, T.3    Kumar, R.4
  • 94
    • 0020664319 scopus 로고
    • Effect on pindolol on stress-related disturbances of musical performance: Preliminary communication
    • James IM, Burgoyne W, Savage IT. Effect on pindolol on stress-related disturbances of musical performance: preliminary communication. J. R. Soc. Med. 76(3), 194-196 (1983).
    • (1983) J. R. Soc. Med , vol.76 , Issue.3 , pp. 194-196
    • James, I.M.1    Burgoyne, W.2    Savage, I.T.3
  • 95
    • 4344610707 scopus 로고    scopus 로고
    • Efficacy and tolerability of controlled-release paroxetine
    • Golden R. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol. Bull. 37(Suppl. 1), 176-186 (2003).
    • (2003) Psychopharmacol. Bull , vol.37 , Issue.SUPPL. 1 , pp. 176-186
    • Golden, R.1
  • 97
    • 0021276677 scopus 로고
    • Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice
    • Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr. Med. Res. Opin. 9(1), 64-70 (1984).
    • (1984) Curr. Med. Res. Opin , vol.9 , Issue.1 , pp. 64-70
    • Allsopp, L.F.1    Cooper, G.L.2    Poole, P.H.3
  • 98
    • 4344645041 scopus 로고    scopus 로고
    • ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder
    • Montgomery SA, Lecrubier Y, Baldwin D et al. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Eur. Neuropsychopharmacol. 14, 425-433 (2004).
    • (2004) Eur. Neuropsychopharmacol , vol.14 , pp. 425-433
    • Montgomery, S.A.1    Lecrubier, Y.2    Baldwin, D.3
  • 99
    • 2442567884 scopus 로고    scopus 로고
    • How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia
    • Lincoln TM, Rief W. How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia. J. Anxiety Disord. 18(4), 515-529 (2004).
    • (2004) J. Anxiety Disord , vol.18 , Issue.4 , pp. 515-529
    • Lincoln, T.M.1    Rief, W.2
  • 100
    • 0037664376 scopus 로고    scopus 로고
    • Schneier FR, Blanco C, Campeas R et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety 17(4), 191-196 (2003). •• A thorough and novel synthesis of randomized controlled trials of pharmacotherapy for SAD. Results of a power analysis revealed that comparisons are insufficiently powered in many cases to detect a statistically significant difference in efficacy between medications. Authors conclude on the basis of a cumulative meta-analysis that sufficient evidence exists to claim with confidence that selective serotonin reuptake inhibitors (SSRIs) and brofaromine are effective in treating this disorder.
    • Schneier FR, Blanco C, Campeas R et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress. Anxiety 17(4), 191-196 (2003). •• A thorough and novel synthesis of randomized controlled trials of pharmacotherapy for SAD. Results of a power analysis revealed that comparisons are insufficiently powered in many cases to detect a statistically significant difference in efficacy between medications. Authors conclude on the basis of a cumulative meta-analysis that sufficient evidence exists to claim with confidence that selective serotonin reuptake inhibitors (SSRIs) and brofaromine are effective in treating this disorder.
  • 101
    • 0034805127 scopus 로고    scopus 로고
    • Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study
    • Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am. J. Psychiatry 158(10), 1725-1727 (2001).
    • (2001) Am. J. Psychiatry , vol.158 , Issue.10 , pp. 1725-1727
    • Stein, M.B.1    Sareen, J.2    Hami, S.3    Chao, J.4
  • 102
    • 39549114184 scopus 로고    scopus 로고
    • Nemeroff CB, Entsuah R, Benattia I et al. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry PMID: 17888885 (2007) (Epub ahead of print). • This study represents the largest comparison of the relative efficacy of antidepressants ever undertaken, presenting the results of a systematic comparison of the efficacy of 8 weeks of treatment with venlafaxine versus individual SSRI agents in 8744 patients from Wyeth sponsored trials of depression. The finding that fluoxetine was the only SSRI which was more effective than venlafaxine was used by the authors to temper the significance of the reported 5.9% advantage of venlafaxine versus SSRIs in remission rates, as over half of the patients treated with SSRIs were receiving fluoxetine.
    • Nemeroff CB, Entsuah R, Benattia I et al. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry PMID: 17888885 (2007) (Epub ahead of print). • This study represents the largest comparison of the relative efficacy of antidepressants ever undertaken, presenting the results of a systematic comparison of the efficacy of 8 weeks of treatment with venlafaxine versus individual SSRI agents in 8744 patients from Wyeth sponsored trials of depression. The finding that fluoxetine was the only SSRI which was more effective than venlafaxine was used by the authors to temper the significance of the reported 5.9% advantage of venlafaxine versus SSRIs in remission rates, as over half of the patients treated with SSRIs were receiving fluoxetine.
  • 103
    • 0031464343 scopus 로고    scopus 로고
    • Social phobia: Long-term treatment outcome and prediction of response - a moclobemide study
    • Versiani M, Amrein R, Montgomery S. Social phobia: long-term treatment outcome and prediction of response - a moclobemide study. Int. Clin. Psychopharmacol. 12(5), 239-254 (1997).
    • (1997) Int. Clin. Psychopharmacol , vol.12 , Issue.5 , pp. 239-254
    • Versiani, M.1    Amrein, R.2    Montgomery, S.3
  • 104
    • 39549090299 scopus 로고    scopus 로고
    • Cognitive behavior therapy versus moclobemide in social phobia
    • Presented at:, Jerusalem, Israel, 16-21 November
    • Oosterbaan D, van Balkom A, Spinhoven, van Dyk R. Cognitive behavior therapy versus moclobemide in social phobia. Presented at: WPA Thematic Conference. Jerusalem, Israel, 16-21 November (1997).
    • (1997) WPA Thematic Conference
    • Oosterbaan, D.1    van Balkom, A.2    Spinhoven3    van Dyk, R.4
  • 105
    • 0029562945 scopus 로고
    • Personality traits in social phobia
    • Fahlen T. Personality traits in social phobia. J. Clin. Psychiatry 56(12), 569-573 (1995).
    • (1995) J. Clin. Psychiatry , vol.56 , Issue.12 , pp. 569-573
    • Fahlen, T.1
  • 106
    • 7044274308 scopus 로고    scopus 로고
    • Co-occurence of 12-month mood and anxiety disorders and personality disorders in the US: Results from the national epidemiologic survey on alcohol and related conditions
    • Grant BF, Hasin DF, Stinson FS. Co-occurence of 12-month mood and anxiety disorders and personality disorders in the US: results from the national epidemiologic survey on alcohol and related conditions. J. Psychiatr. Res. (39), 1-9 (2005).
    • (2005) J. Psychiatr. Res , vol.39 , pp. 1-9
    • Grant, B.F.1    Hasin, D.F.2    Stinson, F.S.3
  • 107
    • 7244254160 scopus 로고    scopus 로고
    • Associations in the course of personality disorders and Axis I disorders over time
    • Shea MT, Stout RL, Yen S et al. Associations in the course of personality disorders and Axis I disorders over time. J. Abnorm. Psychol. 113(4), 499-508 (2004).
    • (2004) J. Abnorm. Psychol , vol.113 , Issue.4 , pp. 499-508
    • Shea, M.T.1    Stout, R.L.2    Yen, S.3
  • 108
    • 33751537253 scopus 로고    scopus 로고
    • An epidemiologic perspective on social anxiety disorder
    • Stein MB. An epidemiologic perspective on social anxiety disorder. J. Clin. Psychiatry 67(Suppl. 12), 3-8 (2006).
    • (2006) J. Clin. Psychiatry , vol.67 , Issue.SUPPL. 12 , pp. 3-8
    • Stein, M.B.1
  • 109
    • 0035701239 scopus 로고    scopus 로고
    • Taijin kyofusho: A form of social anxiety disorder that repsonds to serotonin reuptake inhibitors?
    • Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ. Taijin kyofusho: a form of social anxiety disorder that repsonds to serotonin reuptake inhibitors? Int. J. Neuropsychopharmacol. 4(3), 231-237 (2001).
    • (2001) Int. J. Neuropsychopharmacol , vol.4 , Issue.3 , pp. 231-237
    • Matsunaga, H.1    Kiriike, N.2    Matsui, T.3    Iwasaki, Y.4    Stein, D.J.5
  • 110
    • 0031940749 scopus 로고    scopus 로고
    • Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion
    • Stein DJ, Le Roux L, Bouwer C, Van Heerden B. Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion. J. Neuropsychiatry Clin. Neurosci. 10(1), 96-99 (1998).
    • (1998) J. Neuropsychiatry Clin. Neurosci , vol.10 , Issue.1 , pp. 96-99
    • Stein, D.J.1    Le Roux, L.2    Bouwer, C.3    Van Heerden, B.4
  • 111
    • 0035171845 scopus 로고    scopus 로고
    • Pharmacotherapy of social anxiety disorder at the turn of the millennium
    • Van Ameringen M, Mancini C. Pharmacotherapy of social anxiety disorder at the turn of the millennium. Psychiatr. Clin. North Am. 24(4), 783-803 (2001).
    • (2001) Psychiatr. Clin. North Am , vol.24 , Issue.4 , pp. 783-803
    • Van Ameringen, M.1    Mancini, C.2
  • 112
    • 16544366906 scopus 로고    scopus 로고
    • Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. J. Clin. Psychiatry 65(10, 1400-1405 (2004, • A study assessing the impact of the requirement of clinical significance in diagnosing depression and anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. Based on a sample of outpatients participating in the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the diagnosis of lifetime SAD depended to a greater extent on fulfillment of the criteria of clinical significance than either major depressive disorder or post-traumatic stress disorder
    • Zimmerman M, Chelminski I, Young D. On the threshold of disorder: a study of the impact of the DSM-IV clinical significance criterion on diagnosing depressive and anxiety disorders in clinical practice. J. Clin. Psychiatry 65(10), 1400-1405 (2004). • A study assessing the impact of the requirement of clinical significance in diagnosing depression and anxiety disorders according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. Based on a sample of outpatients participating in the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, the diagnosis of lifetime SAD depended to a greater extent on fulfillment of the criteria of clinical significance than either major depressive disorder or post-traumatic stress disorder.
  • 113
    • 0015583292 scopus 로고
    • Controlled evaluation of intravenous drugs in the specific desensitization of phobias
    • Silverstone JT, Salkind MR. Controlled evaluation of intravenous drugs in the specific desensitization of phobias. Can. Psychiatr. Assoc. J. 18(1), 47-53 (1973).
    • (1973) Can. Psychiatr. Assoc. J , vol.18 , Issue.1 , pp. 47-53
    • Silverstone, J.T.1    Salkind, M.R.2
  • 114
    • 0015579378 scopus 로고
    • Behaviour therapy versus drug therapy in the treatment of phobic neurosis
    • Solyom L, Heseltine GF, McClure DJ et al. Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can. Psychiatr. Assoc. J. 18(1), 25-32 (1973).
    • (1973) Can. Psychiatr. Assoc. J , vol.18 , Issue.1 , pp. 25-32
    • Solyom, L.1    Heseltine, G.F.2    McClure, D.J.3
  • 115
    • 4444260376 scopus 로고    scopus 로고
    • Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders
    • Kuzma JM, Black DW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr. Psychiatry Rep. 6(4), 268-273 (2004).
    • (2004) Curr. Psychiatry Rep , vol.6 , Issue.4 , pp. 268-273
    • Kuzma, J.M.1    Black, D.W.2
  • 116
    • 0030742003 scopus 로고    scopus 로고
    • Bailar JC 3rd. The promise and problems of meta-analysis. N. Engl. J. Med. 337(8), 559-561 (1999).
    • Bailar JC 3rd. The promise and problems of meta-analysis. N. Engl. J. Med. 337(8), 559-561 (1999).
  • 117
    • 0037374008 scopus 로고    scopus 로고
    • Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses
    • Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J. 326(7387), 472 (2003).
    • (2003) Br. Med. J , vol.326 , Issue.7387 , pp. 472
    • Song, F.1    Altman, D.G.2    Glenny, A.M.3    Deeks, J.J.4
  • 118
    • 0036906386 scopus 로고    scopus 로고
    • Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings
    • Atmaca M, Kuloglu M, Tezcan E, Unal A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum. Psychopharmacol. 17(8), 401-405 (2002).
    • (2002) Hum. Psychopharmacol , vol.17 , Issue.8 , pp. 401-405
    • Atmaca, M.1    Kuloglu, M.2    Tezcan, E.3    Unal, A.4
  • 120
    • 0032794768 scopus 로고    scopus 로고
    • Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor nonresponders
    • Altamura A, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor nonresponders. Int. Clin. Psychopharmacol. 14(4), 239-245 (1999).
    • (1999) Int. Clin. Psychopharmacol , vol.14 , Issue.4 , pp. 239-245
    • Altamura, A.1    Pioli, R.2    Vitto, M.3    Mannu, P.4
  • 121
    • 0042326758 scopus 로고    scopus 로고
    • Phenelzine efficacy in refractory social anxiety disorder: A case series
    • Aarre TF. Phenelzine efficacy in refractory social anxiety disorder: a case series. Nord. J. Psychiatry 57(4), 313-315 (2003).
    • (2003) Nord. J. Psychiatry , vol.57 , Issue.4 , pp. 313-315
    • Aarre, T.F.1
  • 122
    • 33846527318 scopus 로고    scopus 로고
    • Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 12(1), 51-61 (2007). • The NMDA agonist d-cycloserine is argued on theoretical grounds and on the basis of animal research to faciliate the extinction learning component of cognitive-behavioral therapy in treating anxiety disorders. The favourable side-effect profile and lack of evidence of affect modulation of low isolated doses of this agent suggest that it may bypass the context-dependence learning thought to account for the dissapointing performance of studies combining medication and psychotherapy in treating this class of disorders.
    • Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr. 12(1), 51-61 (2007). • The NMDA agonist d-cycloserine is argued on theoretical grounds and on the basis of animal research to faciliate the extinction learning component of cognitive-behavioral therapy in treating anxiety disorders. The favourable side-effect profile and lack of evidence of affect modulation of low isolated doses of this agent suggest that it may bypass the context-dependence learning thought to account for the dissapointing performance of studies combining medication and psychotherapy in treating this class of disorders.
  • 123
    • 0026069816 scopus 로고
    • Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study
    • Gelernter CS, Uhde TW, Cimbolic P et al. Cognitive-behavioural and pharmacological treatments of social phobia: a controlled study. Arch. Gen. Psychiatry 48(10), 938-945 (1991).
    • (1991) Arch. Gen. Psychiatry , vol.48 , Issue.10 , pp. 938-945
    • Gelernter, C.S.1    Uhde, T.W.2    Cimbolic, P.3
  • 124
    • 0018762593 scopus 로고
    • Flooding with brevital in the treatment of agoraphobia - countereffective?
    • Chambless D, Foa E, Groves G, Goldstein A. Flooding with brevital in the treatment of agoraphobia - countereffective? Behav. Res. Ther. 17, 243-251 (1979).
    • (1979) Behav. Res. Ther , vol.17 , pp. 243-251
    • Chambless, D.1    Foa, E.2    Groves, G.3    Goldstein, A.4
  • 125
    • 0025022289 scopus 로고
    • Behavior therapy and benzodiazepines: Allies or antagonists?
    • Wardle J. Behavior therapy and benzodiazepines: allies or antagonists? Br. J. Psychiatry 156, 163-168 (1990).
    • (1990) Br. J. Psychiatry , vol.156 , pp. 163-168
    • Wardle, J.1
  • 126
    • 33750283860 scopus 로고    scopus 로고
    • Defining response and remission in anxiety disorders. Towards an integrated approach
    • Bandelow B. Defining response and remission in anxiety disorders. Towards an integrated approach. CNS Spectr. 11(10 Suppl. 12), 21-28 (2006).
    • (2006) CNS Spectr , vol.11 , Issue.10 SUPPL. 12 , pp. 21-28
    • Bandelow, B.1
  • 127
    • 39549116419 scopus 로고    scopus 로고
    • London
    • Kings College London. www.iop.kcl.ac.uk/IoP/ccdan/qrs.htm
    • College, K.1
  • 137
    • 39549107475 scopus 로고    scopus 로고
    • GSK. fMRI study comparing BOLD activation patterns using GW679769 in subjects with social anxiety disorder. http://clinicaltrials.gov/ct/show/ NCT00332046 (Accessed September 2007)
    • GSK. fMRI study comparing BOLD activation patterns using GW679769 in subjects with social anxiety disorder. http://clinicaltrials.gov/ct/show/ NCT00332046 (Accessed September 2007)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.